Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker DYN
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Johanna Friedl-Naderer Chief Commercial Officer | DYN Dyne Therapeutics, Inc. | Sale | 185 | $18.88 | $3,493 Sale | Form 4 ↗ |
| Sep 8, 2026 | Douglas Kerr Chief Medical Officer | DYN Dyne Therapeutics, Inc. | Sale | 1,290 | $18.88 | $24.4K Sale | Form 4 ↗ |
| Sep 8, 2026 | John Cox CEO & President, Director | DYN Dyne Therapeutics, Inc. | Sale | 5,658 | $18.88 | $106.8K Sale | Form 4 ↗ |
| Sep 4, 2026 | Johanna Friedl-Naderer Chief Commercial Officer | DYN Dyne Therapeutics, Inc. | Sale | 900 | $24.35 | $21.9K Sale | Form 4 ↗ |
| Sep 4, 2026 | Douglas Kerr Chief Medical Officer | DYN Dyne Therapeutics, Inc. | Sale | 3,745 | $24.35 | $91.2K Sale | Form 4 ↗ |
| Aug 14, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 322,465 | $25.00 | $8.1M Sale | Form 4 ↗ |
| Aug 14, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 478,377 | $25.00 | $12.0M Sale | Form 4 ↗ |
| Aug 14, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 1.36M | $25.00 | $34.0M Sale | Form 4 ↗ |
| Aug 13, 2026 | Johanna Friedl-Naderer Chief Commercial Officer | DYN Dyne Therapeutics, Inc. | Sale | 226 | $26.28 | $5,939 Sale | Form 4 ↗ |
| Aug 13, 2026 | Douglas Kerr Chief Medical Officer | DYN Dyne Therapeutics, Inc. | Sale | 1,556 | $26.28 | $40.9K Sale | Form 4 ↗ |
| Aug 13, 2026 | Erick Lucera Chief Financial Officer | DYN Dyne Therapeutics, Inc. | Sale | 1,797 | $26.28 | $47.2K Sale | Form 4 ↗ |
| Aug 13, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 63,643 | $26.20 | $1.7M Sale | Form 4 ↗ |
| Aug 13, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 94,415 | $26.20 | $2.5M Sale | Form 4 ↗ |
| Aug 13, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 268,354 | $26.20 | $7.0M Sale | Form 4 ↗ |
| Aug 13, 2026 | John Cox CEO & President, Director | DYN Dyne Therapeutics, Inc. | Sale | 4,986 | $26.28 | $131.0K Sale | Form 4 ↗ |
| Jul 27, 2026 | Dirk Kersten Director | DYN Dyne Therapeutics, Inc. | Sale | 5,388 | $26.04 | $140.3K Sale | Form 4 ↗ |
| Jul 27, 2026 | Dirk Kersten Director | DYN Dyne Therapeutics, Inc. | Sale | 256,072 | $25.50 | $6.5M Sale | Form 4 ↗ |
| Jul 7, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 5,000 | $23.61 | $118.0K Sale | Form 4 ↗ |
| Jul 7, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 11,665 | $23.62 | $275.5K Sale | Form 4 ↗ |
| Jul 7, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 49,193 | $23.17 | $1.1M Sale | Form 4 ↗ |
| Jul 7, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 14,844 | $23.62 | $350.6K Sale | Form 4 ↗ |
| Jul 7, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 62,543 | $23.17 | $1.4M Sale | Form 4 ↗ |
| Jul 7, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 29,587 | $23.62 | $698.8K Sale | Form 4 ↗ |
| Jul 7, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 124,379 | $23.17 | $2.9M Sale | Form 4 ↗ |
| Jul 6, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 100,019 | $22.79 | $2.3M Sale | Form 4 ↗ |
| Jul 6, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 127,182 | $22.79 | $2.9M Sale | Form 4 ↗ |
| Jul 6, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 253,039 | $22.79 | $5.8M Sale | Form 4 ↗ |
| Jun 29, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 40,702 | $21.14 | $860.4K Sale | Form 4 ↗ |
| Jun 29, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 51,756 | $21.14 | $1.1M Sale | Form 4 ↗ |
| Jun 29, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 102,969 | $21.14 | $2.2M Sale | Form 4 ↗ |
| Jun 26, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 64,411 | $21.28 | $1.4M Sale | Form 4 ↗ |
| Jun 26, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 81,903 | $21.28 | $1.7M Sale | Form 4 ↗ |
| Jun 26, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 162,954 | $21.28 | $3.5M Sale | Form 4 ↗ |
| Jun 25, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 5,019 | $21.10 | $105.9K Sale | Form 4 ↗ |
| Jun 25, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 6,382 | $21.10 | $134.7K Sale | Form 4 ↗ |
| Jun 25, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 12,699 | $21.10 | $267.9K Sale | Form 4 ↗ |
| Jun 25, 2026 | Erick Lucera Chief Financial Officer | DYN Dyne Therapeutics, Inc. | Sale | 2,362 | $20.37 | $48.1K Sale | Form 4 ↗ |
| Jun 24, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 19,973 | $21.02 | $419.8K Sale | Form 4 ↗ |
| Jun 24, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 25,397 | $21.02 | $533.8K Sale | Form 4 ↗ |
| Jun 24, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 50,530 | $21.02 | $1.1M Sale | Form 4 ↗ |
| Jun 23, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 30,774 | $21.13 | $650.3K Sale | Form 4 ↗ |
| Jun 23, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 39,131 | $21.13 | $826.8K Sale | Form 4 ↗ |
| Jun 23, 2026 | Jason P. Rhodes Director | DYN Dyne Therapeutics, Inc. | Sale | 77,855 | $21.13 | $1.6M Sale | Form 4 ↗ |
| Jun 23, 2026 | Dirk Kersten Director | DYN Dyne Therapeutics, Inc. | Sale | 1,657 | $21.47 | $35.6K Sale | Form 4 ↗ |
| Jun 23, 2026 | Dirk Kersten Director | DYN Dyne Therapeutics, Inc. | Sale | 71,629 | $21.04 | $1.5M Sale | Form 4 ↗ |
| Jun 22, 2026 | Dirk Kersten Director | DYN Dyne Therapeutics, Inc. | Sale | 190,676 | $20.57 | $3.9M Sale | Form 4 ↗ |
| Jun 18, 2026 | Dirk Kersten Director | DYN Dyne Therapeutics, Inc. | Sale | 46,901 | $20.07 | $941.3K Sale | Form 4 ↗ |
| Jun 17, 2026 | Dirk Kersten Director | DYN Dyne Therapeutics, Inc. | Sale | 37,454 | $20.14 | $754.3K Sale | Form 4 ↗ |
| Jun 16, 2026 | Johanna Friedl-Naderer Chief Commercial Officer | DYN Dyne Therapeutics, Inc. | Sale | 145 | $18.33 | $2,658 Sale | Form 4 ↗ |
| Jun 16, 2026 | Douglas Kerr Chief Medical Officer | DYN Dyne Therapeutics, Inc. | Sale | 887 | $18.33 | $16.3K Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:23 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances